Exact Therapeutics AS to present at DNB Nordic Healthcare Conference on 16th
OSLO/LONDON: 13 DECEMBER, 2021: Exact Therapeutics AS ("EXACT-Tx", or "the
Company" Euronext Growth: EXTX), a clinical-stage precision health company
evaluating Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas,
today announces that its Interim Chief Executive Officer and Chief Financial
Officer, Dominic Moreland and Chief Medical Officer, Dr Hilary McElwaine-Johnn
will present a corporate overview via live webcast at the DNB Nordic Healthcare
Conference 6th at 3:55pm CET. The Management Team is also available for 1:1
meetings with potential partners and investors.
The presentation will be available at www.exact-tx.com.
DNB is Norway's largest financial services group and one of the largest in the
Nordic region in terms of market capitalisation. The Group offers a full range
of financial services, including loans, savings, advisory services, insurance
and pension products for retail and corporate customers.
For more information, please contact:
Optimum Strategic Communications
Mary Clark/ Manel Mateus/ Vici Rabbets
Tel: +44 (0) 208 078 0457
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement
- with the potential to significantly amplify the clinical utility of a wide
range of therapeutic agents across a multitude of indications including within
oncology (chemotherapy, immunotherapy), infectious diseases, and brain diseases.
oACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
oACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
oInitial focus of the Company is in oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and